ADAPY

Adaptimmune Therapeutics PLC

OTCAdd to watchlist

$0.02

−$0.00−7.20%

Delayed · 2026-09-10T20:00:00.000Z · marketstack

Aug 12, 2026$0.02

−$0.01−20.00%over 1M

Day range46% of range

$0.02$0.03

Session

Previous close: $0.03
Open: $0.02
Volume: 63.25K
Avg volume: -
Day high: $0.03
Day low: $0.02

Fundamentals

Visualize fundamentals and more

Market cap: 36.76M
P/E ratio: -
EPS (TTM): -$0.11
Dividend yield: -
Beta: -
Shares outstanding: 1.58B

Source SEC EDGAR · 9/11/2026

Risk factors, year on year

Item 1AMarch 2025 10-KMarch 2024as filed.

added: 133
dropped: 118
re-drafted: 51

Out of 401 passages in this year’s Item 1A.

The assistant has not been given these passages. It will say so, and say what opens them. This costs you no question.

New this year

● Although our financial statements have been prepared on a going concern basis, there is substantial doubt about our ability to continue as a going concern.

250 more passages, included withBespoke

Recent activity

3 more events, included withMeasure

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Ask about Adaptimmune Therapeutics PLC

The assistant answers from what ADAPY has actually filed: 11 annual reports filed with the SEC. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Pressing one answers it here, from ADAPY's filings and figures. One a day without an account; a free account has its own, and no card.

See every investor holding Adaptimmune Therapeutics PLC, and every quarter they moved.

Ten seconds, no card, and nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Adaptimmune Therapeutics PLC

Separate the decisions from the paperwork